Erste AM sees tailwind for biotechnology companies
- Market approval imminent for numerous innovative drugs
- Healthcare spending in OECD countries to increase to 9.5% of GDP by 2050
- Annual increase of 10 to 15% of sales and earnings expected for the biotech sector until 2020
- More than half of all newly approved drugs were based on biotechnology in 2016
- Financial market: increased issue activity in Q2 2017
- Biotech shares with attractive valuations
- Market approval imminent for numerous innovative drugs
- Healthcare spending in OECD countries to increase to 9.5% of GDP by 2050
- Annual increase of 10 to 15% of sales and earnings expected for the biotech sector until 2020
- More than half of all newly approved drugs were based on biotechnology in 2016
- Financial market: increased issue activity in Q2 2017
- Biotech shares with attractive valuations